Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

Publisher: La Merie Publishing
Pages: 76
Product Line:
Competitor Analysis
Format: PDF and Online
Product Code: LMCA0036
Release Date: July of 2015

400.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product portfolios and R&D pipelines of granulocyte colony stimulating factor (G-CSF) and GM-CSF products and product candidates in regulated and in less regulated markets as of July 2015. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

With 2014 sales of about US$ 6 bln, first and next generation G-CSF products represent an attractive market size for biosimilar proteins in regulated markets. Biosimilar filgrastim products have already been introduced into the the European Union and now are also entering the US market. Importantly, biosimilar products from Indian companies are among the approved products indicating that Indian companies can fulfill Western standards of cGMP manufacturing and cGCP development of at least relatively simple therapeutic proteins such as filgrastim.

The report includes a compilation of currently marketed branded and non-branded G-CSF and GM-CSF products in regulated and less regulated markets for treatment of chemotherapy-induced neutropenia. The report includes the market size of branded G-CSF products in 2014. In addition, the report lists company-specific product portfolios and R&D pipelines of G-CSF/GM-CSF products and projects. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

Table of Contents

2014 Sales of Branded Filgrastim, Lenograstim & Pegfilgrastim Products

Filgrastim & Lenograstim: Originator, Biosimilar & Biosuperior Products in EU
Filgrastim: Originator, Biosimilar & Biosuperior Products in USA
Filgrastim, Lenograstim & Nartograstim: Originator, Biosimilar & Biosuperior Products in Japan
Filgrastim: Biosimilar Products in India, Pakistan & Bangladesh
Filgrastim: Biosimilar Products in China & Taiwan
Filgrastim: Biosimilar Products in South Korea
Filgrastim & Lenograstim: Biosimilar Products in Latin America
Filgrastim: Biosimilar Products in Other Less Regulated Markets

Pegfilgrastim: Originator, Biosimilar & Biosuperior Products in EU
Pegfilgrastim: Originator, Biosimilar & Biosuperior Products in USA
Pegfilgrastim: Originator, Biosimilar & Biosuperior Products in Japan
Pegfilgrastim: Biosimilar Products in India & Pakistan
Pegfilgrastim: Biosimilar & Biosuperior Products in China & Taiwan
Pegfilgrastim: Biosimilar & Biosuperior Products in South Korea
Pegfilgrastim: Biosimilar Products in Other Less Regulated Markets

GM-CSF: Sargramostim Originator & Biosimilar Products worldwide
GM-CSF: Molgramostim Originator & Biosimilar Products worldwide

Corporate Filgrastim & Pegfilgrastim Biosimilar & Biosuperior Portfolios



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top